



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/gpss20>

Microwave Assisted Synthesis of Some Pyridine Derivatives Containing Mercaptotriazole and Thiazolidinone as a New Class of Antimicrobial Agents

Sarika Mehta^a, Neelam Swarnkar^a, Ritu Vyas^a,
Jitendra Vardia^a, Pinki B. Punjabi^a & Suresh C.
Ameta^a

^a Microwave Chemistry Laboratory, Department of Chemistry, University College of Science, M. L. Sukhadia University, Udaipur, India
Published online: 20 Feb 2008.

To cite this article: Sarika Mehta, Neelam Swarnkar, Ritu Vyas, Jitendra Vardia, Pinki B. Punjabi & Suresh C. Ameta (2007) Microwave Assisted Synthesis of Some Pyridine Derivatives Containing Mercaptotriazole and Thiazolidinone as a New Class of Antimicrobial Agents, *Phosphorus, Sulfur, and Silicon and the Related Elements*, 183:1, 105-114, DOI: [10.1080/10426500701557138](https://doi.org/10.1080/10426500701557138)

To link to this article: <http://dx.doi.org/10.1080/10426500701557138>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and

are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Microwave Assisted Synthesis of Some Pyridine Derivatives Containing Mercaptotriazole and Thiazolidinone as a New Class of Antimicrobial Agents

Sarika Mehta, Neelam Swarnkar, Ritu Vyas,
Jitendra Vardia, Pinki B. Punjabi, and Suresh C. Ameta
Microwave Chemistry Laboratory, Department of Chemistry,
University College of Science, M. L. Sukhadia University, Udaipur, India

A fast and facile procedure for the synthesis of pyridomercaptotriazole 4a–e and pyridothiazolidinone 5a–e is being reported starting from dihydropyridine 1a–e. Subsequent oxidation with nitrating mixture ($\text{HNO}_3/\text{H}_2\text{SO}_4$) produced the anticipated 2,6-dimethylpyridine derivatives 2a–e, which were subsequently condensed with thiosemicarbazide in ethanol to produce the key intermediate 2,2'-(4-(4-substituted phenyl)-2,6-dimethylpyridine-3,5-diyl)dicarbonyldihydrazine carbothioamides 3a–e. In the final step pyridomercaptotriazole derivatives 4a–e were synthesized by treating 3a–e in alkaline media. In parallel pyridothiazolidinone derivatives 5a–e were obtained by the reaction of 3a–e with $\text{ClCH}_2\text{COOH}/\text{CH}_3\text{COONa}$. All the reactions were carried out on microwave irradiation in good yield with short time. The structures of all the compounds have been confirmed on the basis of their analytical, IR, ^1H NMR, and Mass spectral data (Tables I and II). The potent antimicrobial effects of the synthesized compounds were also investigated.

Keywords Dihydropyridine; dihydrazinocarbothioamide; green chemical synthesis; mercaptotriazole; microwave protocol; thiazolidinone

INTRODUCTION

In times where a premium is put on speed, diversity and efficiency in the drug discovery process, MAOS¹ (Microwave Assisted Organic

Received 5 May 2007; Accepted 5 June 2007.

The authors are thankful to Head, Department of Chemistry, M. L. Sukhadia University, Udaipur (Raj.) for providing laboratory facilities. The authors are also thankful to the Director, RSIC, CDRI, Lucknow, for spectral and analytical studies. Additionally, one of the authors (SM) is thankful to CSIR-New Delhi and one of the authors (RV) is thankful to UGC-New Delhi for providing necessary financial assistance.

Address correspondence to Suresh C. Ameta, Microwave Chemistry Laboratory, Department of Chemistry, University College of Science, M. L. Sukhadia University, Udaipur 313002, India. E-mail: ameta_sc@yahoo.com

Synthesis) strategies offer significant advantages over conventional synthesis. Considering these benefits, the present article reports a convenient green chemical synthesis^{2,3} methods of mercaptotriazole,⁴ and thiazolidinone⁵ derivatives by means of a four-pot reaction route using dihydropyridine as starting material. The formation of heterocyclic rings by cyclocondensation reaction^{6–9} is typically a process well suited for microwave technology. The starting nuclei dihydropyridine was synthesized according to reported method using microwave protocol.¹⁰ In spite of literature reported on the chemistry of dihydropyridine and pyridine¹¹ nucleus, no attention has been paid to the chemistry of pyridine nucleus containing thiosemicarbazide^{12,13} groups, although it should be an excellent material for synthesis of targeted moieties of the present study. This work assumes importance in view of the fact that pyridine derivatives display a number of important biological activities such as antimicrobial,¹⁴ anticonvulsant, antiparkinsonian, and analgesic¹⁵ and hence possess great chemotherapeutic potential. Moreover synthesis of mercaptotriazole has attracted widespread attention due to their diverse applications as anti-inflammatory,¹⁶ antimycotic,¹⁷ and antinociceptive¹⁸ activity. Along with this a vast amount of published material is available describing a wide range of biological activity^{19–21} of thiazolidinone derivatives. Thus with an effort to capitalize the pharmacological potential of the above nucleus and to improve the efficiency, output and quality of the process, the present work reports on the formation of targeted moieties by the annulations and fictionalization of pyridine derivatives under microwave irradiation.


RESULTS AND DISCUSSION

The first step of this multistep sequence involves an important microwave mediated MCR (Multicomponent Reaction), which is the Hantzsch synthesis of dihydropyridine by the condensation of methylacetoacetate, ammonia, and various aromatic aldehydes. The main building blocks 2, 6-dimethylpyridine derivatives **2a–e** were obtained by the oxidation of **1a–e** with nitrating mixture ($\text{HNO}_3/\text{H}_2\text{SO}_4$). The next microwave-driven conversion of ester derivatives **2a–e** into thiosemicarbazide derivatives **3a–e** were completed under mildly basic condition using pyridine as catalyst and provided the desired product in overall yield and purity. The structures of compounds **3a–e** were established by analytical and spectral data. The IR spectrum of **3a** showed the presence of N–H str. at 3338 cm^{-1} and C=S

str. at 1228 cm^{-1} and its ^1H NMR spectrum displayed a singlet for four protons around δ 6.70 due to two equivalent $-\text{NH}_2$ group. **3a** also gave one singlet centered at δ 9.83 due to $-\text{NH}$ proton adjacent to $\text{C}=\text{O}$ group and one singlet centered at δ 9.60 due to $-\text{NH}$ proton adjacent to $\text{C}=\text{S}$ group. Subsequent intramolecular cyclization reaction in the presence of alkaline media (1N NaOH solution) afforded **5**, 5'-[4-(4-substituted phenyl)-2, 6-dimethylpyridine-3, 5-diyl]-bis-(4H)-1, 2, 4-triazole-3-thiol **4a-e**. Among these derivatives **4a** possessed the strong $-\text{SH}$ band around 2530 cm^{-1} in IR spectra and $-\text{NH}$ band at 3430 cm^{-1} . The ^1H NMR spectra of **4a** gave a singlet at δ 11.48 for two protons of two equivalents $-\text{SH}$ group and one singlet at δ 12.60 for two protons of two equivalents $-\text{NH}$ group of mercaptotriazole moieties. Another pathway of this step involves cyclocondensation of **3a-e** with $\text{ClCH}_2\text{COOH}/\text{CH}_3\text{COONa}$ produced the anticipated thiazolidinone derivatives 4-(4-substituted phenyl)-2, 6-dimethyl pyridine N^3 , N^5 -bis-(4-oxo-1, 3-thiazolidin-2-ylidene)-pyridine-3, 5-dicarbohydrazide **5a-e**. The IR spectra of **5a** gave two sharp peaks at 1705 and 1680 cm^{-1} corresponding to $\text{C}=\text{O}$ str. present in thiazolidinone ring and adjacent to pyridine ring respectively, it also gave a strong $-\text{NH}$ band at 3426 cm^{-1} . A characteristic C-S-C band of thiazolidinone ring appeared at 699 cm^{-1} . The ^1H NMR spectra of **5a** displayed a singlet around δ 4.20 for four protons of two equivalents $-\text{CH}_2$ groups of two thiazolidinone moieties. Finally, conclusive evidence has been gathered from the Mass spectra of all final compounds. The reaction depicted in Scheme 1 is one of the growing numbers of examples where not only one, but all steps in the sequence have been performed by microwave dielectric heating.

EXPERIMENTAL

All the melting points were determined in open capillaries. TLC on silica gel-G-plates was used to access the reaction and purity of the synthesized compounds using ethyl acetate: n-hexane (7:3) as irrigant. IR spectra (KBr Pallets) were recorded on Perkin-Elmer 1800 (FTIR) Spectrometer. ^1H NMR spectra ($\text{DMSO}-d_6$) were taken in a Bruker DRX spectrometer (300 MHz FT NMR) using TMS as internal standard and chemical shift are expressed in δ ppm and Mass spectra were taken on Jeol sx-102/PA-6000 (EI) spectrometer. Elemental analyses were performed by Perkin Elmer series C, H, N, and S analyzer-2400. Reactions were carried out in a domestic microwave oven (Kenstar, OM-26 EGO).



SCHEME 1

Synthesis of Dimethyl-4-(4-substituted phenyl)-2, 6-dimethyl 1, 4-dihydropyridine-3,5-dicarboxylate (1a-e)

These compounds were prepared according to a reported Hantzsch synthesis method.¹⁰

Synthesis of Dimethyl-4-(4-substituted phenyl)-2, 6-dimethylpyridine-3, 5-dicarboxylates (2a-e)

Compounds **1a-e** (10 mmol) (**1a** = 3.19 g, 10 mmol) were dissolved in ice-cold water and nitrating mixture (HNO₃/H₂SO₄ in 3:1 ratio) was added to it. Then reaction mixture was irradiated under microwave till yellow color solution is obtained. After cooling the reaction mixture, it

was poured in ice-cold water and neutralized by ammonia solution. The solid thus obtained was recrystallized from ethanol to give **2a–e**.

Synthesis of 2, 2'-[4-(4-Substituted phenyl)-2, 6-dimethylpyridine-3,5-di-yl]-dicarbonyl dihydrazine carbothioamides (**3a–e**)

A mixture of **2a–e** (10 mmol) (**2a** = 3.17 g, 10 mmol) and thiosemicarbazide (1.82 g, 20 mmol) in ethanol was heated under microwave for 8.0–10.0 min. using pyridine in catalytic amount and then allowed to cool in ice-bath overnight. The resulting solid was filtered and recrystallized from ethanol to give **3a–e**.

Synthesis of 5, 5'-[4-(4-Substituted phenyl)-2, 6-dimethylpyridine-3, 5-diyl]-bis-(4H)-1, 2, 4-triazole-3-thiol (**4a–e**)

A reaction mixture of **3a–e** (10 mmol) (**3a** = 4.35 g, 10 mmol) and NaOH (1N, 25 mL) was refluxed for 1.50–3.30 min under microwave. The reaction mixture was cooled, diluted with water, and filtered. The filtrate on acidification with glacial acetic acid gave the crude product, which was filtered, washed with water, and recrystallized from ethanol to give **4a–e**.

Synthesis of 4-(4-Substituted phenyl)-2, 6-dimethylpyridine N³, N⁵-bis-(4-oxo-1, 3-thiazolidin-2ylidene)-pyridine-3, 5-dicarbohydrazide (**5a–e**)

To a suspension of compounds **3a–e** (10 mmol) (**3a** = 4.35 g, 10 mmol), in absolute alcohol, chloroacetic acid (1.88 g, 20 mmol) and anhydrous sodium acetate (3.28 g, 40 mmol) was added. The solution was heated under microwave irradiation for 6.00–8.30 min. Resulting solution was cooled and left for overnight. Solid thus obtained, was filtered, washed with water, and recrystallized from ethanol.

ANTIMICROBIAL ACTIVITY

Preliminary antimicrobial susceptibility tests for all the synthesized pyridomercaptotriazole **4a–e** and pyridothiazolidinone **5a–e** were performed by using cup and well method²² at a concentration of 500 ppm against some selected pathogenic strains—*Pseudomonas aeruginosa*, *Proteus mirabilis*, *Klebsiella pneumoniae*, and *Bacillus subtilis*

TABLE I Physical and Analytical Data of Compounds

Compd. no.	Molecular formula	M.p. (C)	Yield (%)	Elemental analysis calculated (found)			
				C	H	N	S
3a	C ₁₇ H ₁₈ N ₇ S ₂ O ₂ F	210	65	46.89 (45.52)	4.13 (3.25)	22.52 (21.21)	14.71 (13.98)
3b	C ₁₇ H ₁₈ N ₇ S ₂ O ₂ Cl	200	62	45.13 (44.25)	3.98 (2.80)	21.68 (20.23)	14.15 (13.90)
3c	C ₁₈ H ₂₁ N ₇ S ₂ O ₃	265	68	48.32 (47.50)	4.69 (4.10)	21.92 (20.20)	14.31 (13.90)
3d	C ₁₇ H ₁₈ N ₈ S ₂ O ₄	245	58	44.85 (43.55)	3.89 (3.22)	24.24 (23.21)	13.85 (12.50)
3e	C ₁₇ H ₁₉ N ₇ S ₂ O ₂	211	65	53.54 (52.20)	3.93 (3.20)	25.72 (23.45)	16.79 (15.10)
4a	C ₁₇ H ₁₄ N ₇ S ₂ F	210	65	51.12 (50.52)	3.50 (3.25)	24.56 (22.21)	16.04 (15.98)
4b	C ₁₇ H ₁₄ N ₇ S ₂ Cl	200	62	49.15 (47.25)	3.37 (3.20)	23.61 (22.23)	15.48 (14.90)
4c	C ₁₈ H ₁₇ N ₇ S ₂ O	265	68	52.55 (51.50)	4.13 (4.10)	23.84 (21.20)	15.57 (14.10)
4d	C ₁₇ H ₁₄ N ₈ S ₂ O ₂	245	58	47.88 (45.55)	3.28 (3.22)	26.29 (24.24)	15.02 (14.50)
4e	C ₁₇ H ₁₈ N ₇ S ₂	211	65	53.54 (52.20)	3.93 (3.20)	25.72 (23.45)	16.79 (15.10)
5a	C ₂₁ H ₁₈ N ₇ S ₂ F	196	69	48.93 (46.88)	3.49 (3.44)	19.02 (17.88)	12.42 (11.25)
5b	C ₁₇ H ₁₄ N ₇ S ₂ F	200	65	47.45 (45.41)	3.38 (3.10)	18.45 (17.45)	12.05 (11.45)
5c	C ₁₇ H ₁₄ N ₇ S ₂ F	180	70	50.09 (49.10)	3.98 (3.10)	18.59 (16.69)	12.14 (11.00)
5d	C ₁₇ H ₁₄ N ₇ S ₂ F	132	59	46.49 (44.45)	3.32 (3.02)	20.66 (19.10)	11.80 (10.10)
5e	C ₁₇ H ₁₄ N ₇ S ₂ F	140	62	50.70 (49.10)	3.82 (2.96)	19.71 (17.14)	12.87 (11.14)

TABLE II Spectral Data of Compounds

Compd. no.	IR (cm ⁻¹)	¹ H NMR (δ)	MS (m/z)
3a	3338 (NH), 3080 (Ar-H), 1690 (C=O), 1638 (C=N), 1228 (C=S), 1185 (C-F)	2.76 (s, 6H, CH ₃), 6.70 (s, 4H, NH ₂), 7.43-7.83 (m, 4H, Ar-H), 9.60 (s, 2H, NH-C=O), 9.83 (s, 2H, NH-C=O)	—
3b	3326 (NH), 3068 (Ar-H), 1678 (C=O), 1622 (C=N), 1220 (C=S), 757 (C-Cl)	2.72 (s, 6H, CH ₃), 6.64 (s, 4H, NH ₂), 7.39-7.79 (m, 4H Ar-H), 9.59 (s, 2H, NH-C=O), 9.80 (s, 2H, NH-C=O)	—
3c	3328 (NH), 3058 (Ar-H), 1682 (C=O), 1628 (C=N), 1218 (C=S), 1080 (C-O)	2.69 (s, 6H, CH ₃), 3.90 (s, 3H, OCH ₃), 6.59 (s, 4H, NH ₂), 7.29-7.71 (m, 4H Ar-H), 9.53 (s, 2H, NH-C=O), 9.76 (s, 2H, NH-C=O)	—
3d	3325 (NH), 3040 (Ar-H), 1684 (C=O), 1620, (C=N), 1550, 1346 (NO ₂ sym. asym.), 1215 (C=S)	2.75 (s, 6H, CH ₃), 6.68 (s, 4H, NH ₂), 7.35-7.74 (m, 4H Ar-H), 9.49 (s, 2H, NH-C=O), 9.70 (s, 2H, NH-C=O)	—
3e	3320 (NH), 3032 (Ar-H), 1692 (C=O), 1632 (C=N), 1226 (C=S)	2.67 (s, 6H, CH ₃), 6.60 (s, 4H, NH ₂), 7.31-7.73 (m, 4H Ar-H), 9.48 (s, 2H, NH-C=O), 9.79 (s, 2H, NH-C=O)	—
4a	3430 (NH), 3032 (Ar-H), 2530 (SH), 1632 (C=N), 1181 (C-F)	2.75 (s, 6H, CH ₃), 7.63-7.87 (m, 4H Ar-H), 11.48 (s, 2H, SH), 12.60 (s, 2H, NH)	399, 372, 369, 365, 358, 345, 332, 265, 199, 95
4b	3425 (NH), 3001 (Ar-H), 2537 (SH), 1640 (C=N), 751 (C-Cl)	2.70 (s, 6H, CH ₃), 7.59-7.91 (m, 4H Ar-H), 11.25 (s, 2H, SH), 12.55 (s, 2H, NH)	417, 415, 388, 385, 381, 374, 361, 348 281, 215, 111
4c	3428 (NH), 3018 (Ar-H), 2529 (SH), 1638 (C=N), 1072 (C-O)	2.63 (s, 6H, CH ₃), 3.87 (s, 3H, OCH ₃), 7.54-7.88 (m, 4H Ar-H), 11.19 (s, 2H, SH), 12.51 (s, 2H, NH)	411, 384, 381, 377, 370, 357, 344, 277, 211, 107

(Continued on next page)

TABLE II Spectral Data of Compounds (Continued)

Compd. no.	IR (cm ⁻¹)	¹ H NMR (δ)	MS (m/z)
4d	3420 (NH), 3015 (Ar-H), 2530 (SH), 1628 (C=N) 1540, 1338 (NO ₂ sym. asym.)	2.61 (s, 6H, CH ₃), 7.56–7.86 (m, 4H Ar-H), 11.23 (s, 2H, SH), 12.49 (s, 2H, NH)	426, 399, 396, 392, 385, 372, 359, 292, 226, 122
4e	3410 (NH), 3008 (Ar-H), 2532 (SH), 1636 (C=N),	2.66 (s, 6H, CH ₃), 7.21–7.78 (m, 4H Ar-H), 11.20 (s, 2H, SH), 12.41 (s, 2H, NH)	381, 354, 351, 347, 340, 327, 314, 247, 181, 77, 51
5a	3426 (NH), 3012 (Ar-H), 1705 (C=O-thiazolidi none), 1680 (C=O), 1116 (C-F), 699 (C-S-C)	2.67 (s, 6H, CH ₃), 4.20 (s, 4H, CH ₂), 7.38–8.31 (m, 4H Ar-H) 8.69 (s, 2H, NH), 9.57 (s, 2H, NH)	515, 485, 474, 456, 451, 402, 397, 367, 114, 95
5b	3420 (NH), 3041 (Ar-H), 1700 (C=O-thiazolidi none), 1678 (C=O), 1620 (C=N), 757 (C-Cl), 700 (C-S-C)	2.60 (s, 6H, CH ₃), 4.15 (s, 4H, CH ₂), 7.32–8.25 (m, 4H Ar-H) 8.62 (s, 2H, NH), 9.50 (s, 2H, NH)	533, 531, 501, 490, 472, 467, 417, 413, 383, 111
5c	3410 (NH), 3020 (Ar-H), 1708 (C=O-thiazolidi none), 1627 (C=O), 1622 (C=N), 1048 (C-O), 689 (C-S-C)	2.57 (s, 6H, CH ₃), 3.83 (s, 3H, OCH ₃), 4.21 (s, 4H, CH ₂), 7.20–8.15 (m, 4H Ar-H)	527, 497, 486, 468, 463, 413, 379, 114, 107
5d	3415 (NH), 3015 (Ar-H), 1702 (C=O-thiazolidi none), 1679 (C=O), 1618 (C=N), 1540, 1356 (NO ₂ sym. asym.), 692 (C-S-C)	2.54 (s, 6H, CH ₃), 4.16 (s, 4H, CH ₂), 7.26–8.23 (m, 4H Ar-H), 8.67 (s, 2H, NH), 9.53 (s, 2H, NH)	542, 512, 501, 483, 478, 428, 424, 394, 122, 114
5e	3410 (NH), 3005 (Ar-H), 1701 (C=O-thiazolidi none), 1672 (C=O), 1626 (C=N), 695 (C-S-C)	2.64 (s, 6H, CH ₃), 4.18 (s, 4H, CH ₂), 7.36–8.22 (m, 4H Ar-H), 8.50 (s, 2H, NH), 9.55 (s, 2H, NH)	497, 467, 456, 438, 433, 383, 379, 114, 76, 51

TABLE III Antimicrobial Activity of some Synthesized Compounds—Zone of Inhibition (mm) (Activity Index)*

Compd.	Antibacterial Activity (500 ppm)				Antifungal Activity (500 ppm)	
	<i>P. aeruginosa</i>	<i>P. mirabilis</i>	<i>K. pneumoniae</i>	<i>B. subtilis</i>	<i>A. fumigatus</i>	<i>C. albicans</i>
4a	9 (0.56)	20 (0.86)	—	—	23 (1.15)	12 (0.85)
4b	14 (0.87)	21 (0.91)	8 (0.66)	7 (0.63)	21 (1.05)	10 (0.71)
4c	10 (0.62)	20 (0.86)	—	—	18 (0.90)	9 (0.64)
4d	13 (0.81)	17 (0.74)	—	—	17 (0.85)	8 (0.57)
4e	12 (0.75)	15 (0.65)	—	—	17 (0.85)	5 (0.35)
5a	11 (0.68)	18 (0.78)	—	—	19 (0.95)	13 (0.92)
5b	10 (0.62)	20 (0.86)	10 (0.83)	—	21 (1.05)	11 (0.78)
5c	12 (0.75)	16 (0.69)	7 (0.58)	—	16 (0.80)	10 (0.71)
5d	10 (0.62)	13 (0.56)	—	—	14 (0.70)	11 (0.78)
5e	6 (0.37)	12 (0.52)	—	—	15 (0.75)	8 (0.57)
C ₁	16	23	12	11	—	—
C ₂	—	—	—	—	20	14

*Activity index = Inhibition area of the sample/inhibition area of the standard; C₁ = Ciprofloxacin; C₂ = Amphotericin B. Diameter of disc in 5 mm.

were used for bacterial activity and *Aspergillus fumigatus* and *Candida albicans* for antifungal activity. Commercial antibacterial Ciprofloxacin and antifungal Amphotericin B were also screened under similar conditions for comparison. The results have been tabulated in the form of inhibition zones and an activity index in Table III.

The results reveal that all the synthesized compounds have shown moderate to good activity against *P. mirabilis* and *P. aeruginosa* while compounds showed nil activity against *K. pneumoniae*, *B. subtilis*. In case of antifungal activity compounds **4a**, **4b**, and **5b** showed a better activity than standard and compounds **4c**, **5a**, and **5c** exhibited comparable activity to standard drug and remaining compounds exhibited moderate activity as compare to the standard. Although all the compounds show less to moderate activity against bacteria, they possess very strong activity against fungi, which reveals that pyridomercapto-triazole and pyridothiazolidinone derivatives are better antifungal agents as compared to antibacterial.

CONCLUSION

We have developed a fast and convenient microwave assisted procedure for the rapid generation of **4a–e** and **5a–e** by key intermediate **3a–e**. All the reactions were completed within 4–10 minutes of microwave

irradiation and give the desired products in high yields and excellent purities. Further structural identification was achieved by elemental and spectral data. Further, it is observed that some of the screened compounds were highly active against the test microorganism.

REFERENCES

- [1] S. Crosignani, D. Launay, B. Linclau, and M. Bradley, *Mol. Diversity*, **7**, 203 (2003).
- [2] S. Galema, *Chem. Soc. Rev.*, **26**, 233 (1997).
- [3] S. Caddick, *Tetrahedron*, **51**, 373 (1995).
- [4] M. Koparir (Koparır), A. Cetin, and A. Cansiz, *Molecules*, **10**, 475 (2005).
- [5] M. Metwally, H. Etman, E. Keshk, A. Fekry, *Phosphorus, Sulfur, and Silicon, and the Related Elements*, **181**, 1039 (2006).
- [6] N. Srinivasan, and A. Ganesan, *Chem. Commun.*, 916 (2003).
- [7] M. E. Theoclitou, and L. A. Robinson, *Tetrahedron Lett.*, **43**, 3907 (2002).
- [8] a) Z. Zhao, W. H. Leister, K. A. Strauss, D. D. Wisnoski, and C. W. Lindsley, *Tetrahedron Lett.*, **44**, 1123 (2003); b) C. W. Lindsley, D. D. Wisnoski, Y. Wang, W. H. Leister, and Z. Zhao, *Tetrahedron Lett.*, **44**, 4495 (2003).
- [9] a) N. Mont, J. Teixidó, J. I. Borell, and C. O. Kappe, *Tetrahedron Lett.*, **44**, 5385 (2003); b) N. Mont, J. Teixidó, J. I. Borell, and C. O. Kappe, *Mol. Diversity*, **7**, 153 (2003).
- [10] L. Öhberg, and J. Westman, *Synlett*, 1296 (2001).
- [11] A. Mobinikhaledi, and N. Foroughifar, *Phosphorus, Sulfur, and Silicon, and the Related Elements*, **181**, 405 (2006).
- [12] a) A. Varvaresou, A. Tsantili-Kakoulidou, T. Siatra-Papastasikoudi, and E. Tiligada, *Arzneimittelforschung*, **50**, 48 (2000); b) A. Varvaresou, T. Siatra-Papastasikoudi, A. Tsontinis, A. Tsantili-Kakoulidou, and A. Vamvakides, *Farmaco*, **53**, 320 (1998).
- [13] Heravi Majid, Nami Navabeh, Oskooie Hossein, Heknat Shoar, and Rahim, *Phosphorus, Sulfur, and Silicon, and the Related Elements*, **181**, 87 (2006).
- [14] M. E. Azab, G. A. El-Hag Ali, and A. H. Abd El-Waheb, *Acta Pharm*, **53**, 213 (2003).
- [15] G. Amr Acl, H. H. Sayed, and M. M. Abdulla, *Arch Pharm (Weinheim)*, **338**, 433 (2005).
- [16] L. Labanauskas, V. Kalcas, E. Udrenaite, P. Gaidelis, A. Brukstus, and V. Dauksas, *Pharmazie*, **56**, 617 (2001).
- [17] M. Wujec, M. Pitucha, M. Dobosz, U. Kosikowska, and A. Malm, *Acta Pharm*, **54**, 251 (2004).
- [18] M. Gokce, B. Cakir, K. Erol, and M. F. Sahin, *Arch. Pharm.*, **334**, 279 (2001).
- [19] Y. Tanabe, H. Yamamoto, M. Murakami, K. Yanagi, Y. Kubota, H. Okumura, Y. Sanemitsu, and G. Suzukamo, *J. Chem. Soc. Perkin Trans I*, **7**, 935 (1995).
- [20] A. Rao, A. Carbone, A. Chimirri, E. De Clercq, A. M. Monforte, P. Monforte, C. Pannecouque, and M. Zappalá, *Il Farmaco*, **58**, 115 (2003).
- [21] A. Rao, J. Balzarini, A. Carbone, A. Chimirri, E. De Clercq, A. M. Monforte, P. Monforte, C. Pannecouque, and M. Zappalá, *Il Farmaco*, **59**, 33 (2004).
- [22] G. J. Collee, G. A. Fraser, P. B. Mamion, and A. Suninous, *Practical Medical Microbiology 14th Ed.* Vol. **11**, Churchill Livingstone, Eclibury, 163 (1996).